Researchers at the Institute of Science Tokyo developed an mRNA vaccine that suppresses pathological blood vessel growth in mouse models of age-related macular degeneration (AMD). Delivered intramuscularly, this vaccine offers a less invasive alternative to current ocular anti-angiogenic injections, potentially improving patient comfort and treatment adherence for neovascular eye diseases.